A Phase II Study of Low Dose Algenpantucel-L (HyperAcute Pancreas) Cancer Vaccine in Subjects With Surgically Resected Pancreatic Cancer
Phase of Trial: Phase II
Latest Information Update: 01 Jul 2015
At a glance
- Drugs Algenpantucel-L (Primary) ; Antineoplastics
- Indications Pancreatic cancer
- Focus Therapeutic Use
- Sponsors NewLink Genetics Corporation
- 30 May 2014 Planned End Date changed from 1 Sep 2013 to 1 Dec 2014 as reported by ClinicalTrials.gov.
- 07 Aug 2013 Result were presented at ASCO 2013, according to a NewLink Genetics Corporation media release.
- 20 Sep 2011 Planned end date changed from 1 Sep 2010 to 1 Sep 2012 as reported by ClinicalTrials.gov.